PRME logo

PRME
Prime Medicine Inc

2,632
Mkt Cap
$702.35M
Volume
2.13M
52W High
$6.94
52W Low
$1.11
PE Ratio
-2.77
PRME Fundamentals
Price
$3.81
Prev Close
$3.89
Open
$3.89
50D MA
$3.67
Beta
2.18
Avg. Volume
2.71M
EPS (Annual)
-$1.35
P/B
5.69
Rev/Employee
$31,726.03
$454.94
Loading...
Loading...
News
all
press releases
Wall Street Zen Upgrades Prime Medicine (NASDAQ:PRME) to Sell
Wall Street Zen upgraded Prime Medicine from a "strong sell" rating to a "sell" rating in a research note on Sunday...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Sumitomo Mitsui Trust Group Inc. Sells 384,418 Shares of Prime Medicine, Inc. $PRME
Sumitomo Mitsui Trust Group Inc. lowered its holdings in Prime Medicine, Inc. (NASDAQ:PRME - Free Report) by 10.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities...
MarketBeat·4d ago
News Placeholder
Prime Medicine Appoints Svetlana Makhni As Chief Financial Officer
(RTTNews) - Prime Medicine, Inc. (PRME), a developer of a new class of differentiated one-time curative genetic therapies, said on Thursday that it has appointed Svetlana Makhni as Chief Financial...
Nasdaq News: Markets·6d ago
News Placeholder
Prime Medicine (NASDAQ:PRME) Downgraded to "Strong Sell" Rating by Wall Street Zen
Wall Street Zen downgraded Prime Medicine from a "sell" rating to a "strong sell" rating in a research report on Saturday...
MarketBeat·11d ago
News Placeholder
Prime Medicine (NASDAQ:PRME) Trading Down 6.4% - Here's What Happened
Prime Medicine (NASDAQ:PRME) Shares Down 6.4% - Here's What Happened...
MarketBeat·11d ago
News Placeholder
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step PR Newswire VANCOUVER, BC, March 31, 2026 Issued on behalf of Ava Bio...
PR Newswire·21d ago
News Placeholder
Prime Medicine, Inc. (NASDAQ:PRME) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine analysts that are covering the company, Marketbeat reports. One...
MarketBeat·22d ago
News Placeholder
Prime Medicine (NASDAQ:PRME) Stock Price Down 7.3% - What's Next?
Prime Medicine (NASDAQ:PRME) Trading Down 7.3% - What's Next...
MarketBeat·25d ago
News Placeholder
Prime Medicine (NASDAQ:PRME) Trading Up 5.6% - Time to Buy?
Prime Medicine (NASDAQ:PRME) Trading 5.6% Higher - Still a Buy...
MarketBeat·26d ago
News Placeholder
Advanced Cell-based Therapy Booming the Success for Healthcare Sector
Advanced Cell-based Therapy Booming the Success for Healthcare Sector Advanced Cell-based Therapy Booming the Success for Healthcare Sector PR Newswire VANCOUVER, BC, March 24, 2026 Issued on behalf...
PR Newswire·28d ago
<
1
2
...
>

Latest PRME News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.